ProtoKinetix Stock

ProtoKinetix Equity

The The Equity of ProtoKinetix (PKTX) as of Aug 3, 2026 is 342,090.00 USD. In the previous year, The Equity was 435,861.00 USD — a change of -21.51% (lower).

Equity

342,090.00USD

YoY

-21.51%

Last updated:

In 2026, ProtoKinetix's equity was 342,090.00 USD, a -21.51% increase from the 435,861.00 USD equity in the previous year.

Access this data via the Eulerpool API

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Equity Details

Analyzing ProtoKinetix's Equity

ProtoKinetix's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ProtoKinetix's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ProtoKinetix's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ProtoKinetix's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ProtoKinetix’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ProtoKinetix stock

The Equity of ProtoKinetix is 342,090.00 USD in 2026.

The Equity of ProtoKinetix changed from 435,861.00 USD to 342,090.00 USD, representing a -21.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ProtoKinetix

All Key Metrics — ProtoKinetix